# A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

> **NCT05734807** · PHASE2 · COMPLETED · sponsor: **Huahui Health** · enrollment: 74 (actual)

## Conditions studied

- Chronic HBV Infection

## Interventions

- **DRUG:** Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)
- **DRUG:** HH-003 and NrtIs
- **DRUG:** HH-003, NrtIs and PEG-IFN-α

## Key facts

- **NCT ID:** NCT05734807
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-20
- **Primary completion:** 2024-04-17
- **Final completion:** 2024-04-17
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05734807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05734807, "A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05734807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*